NCT01239342 2019-10-10
Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
Clinical Trials
7 trialsNCT01776008 2018-05-08
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01319539 2017-08-30
MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01186705 2015-11-18
Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01239355 2015-10-05
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01466868 2014-07-10
AKTIL
Centre Leon Berard
Phase 2 Terminated
NCT01519427 2014-06-18
Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or Dabrafenib
National Cancer Institute (NCI)
Phase 2 Terminated